Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Lei You

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-6030-6560; OpenAlex author ID A5004208059, A5100299580. Sources: OpenAlex.

Their work

Papers
111 (first author 3, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
134
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 5 papers · 2014: 10 papers · 2015: 5 papers · 2016: 9 papers · 2017: 6 papers · 2018: 9 papers · 2019: 8 papers · 2020: 20 papers · 2021: 15 papers · 2022: 3 papers · 2023: 3 papers · 2024: 9 papers · 2025: 3 papers · 2026: 3 papers

Papers 50 of 111

  1. Artificial intelligence: Catalyzing a new era in pancreatic cancer cure. Co-author DOI 10.1016/j.canlet.2026.218558↗
  2. TRDMT1-mediated mRNA m5C methylation decreases chemotherapy sensitivity by activating homologous recombination-mediated DNA damage repair and IRS2 expression i… Co-author DOI 10.1016/j.canlet.2026.218725↗
  3. [Expression of Concern] c‑Fos/ERK promotes the progression from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/or.2026.9092↗
  4. Comparative spatial transcriptomics of pancreatic cancer with ductal and acinar origins in mouse models. Co-author DOI 10.1002/ctm2.70416↗
  5. Decipher the single-cell level responses to chemotherapy in pancreatic ductal adenocarcinoma by a cross-time context graph model. Co-author DOI 10.1016/j.canlet.2025.217751↗
  6. Machine learning based identification of an amino acid metabolism related signature for predicting prognosis and immune microenvironment in pancreatic cancer. Co-author DOI 10.1186/s12885-024-13374-4↗
  7. Crosstalk between metabolic remodeling and epigenetic reprogramming: A new perspective on pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.216649↗
  8. Histone lactylation dynamics: Unlocking the triad of metabolism, epigenetics, and immune regulation in metastatic cascade of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.217117↗
  9. Comprehensive multi-omics profiling identifies novel molecular subtypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.gendis.2023.101143↗
  10. Pancreatic ductal adenocarcinoma chemoresistance: From metabolism reprogramming to novel treatment. Co-author DOI 10.1097/cm9.0000000000002758↗
  11. Integrated analysis of microbiome and metabolome reveals signatures in PDAC tumorigenesis and prognosis. Co-author DOI 10.1128/spectrum.00962-24↗
  12. Comprehensive analysis of bulk and single-cell transcriptomic data reveals a novel signature associated with endoplasmic reticulum stress, lipid metabolism, an… Co-author DOI 10.1186/s12967-024-05158-y↗
  13. CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment. Co-author DOI 10.1186/s13046-024-03201-w↗
  14. Human Equilibrative Nucleoside Transporter 1: Novel Biomarker and Prognostic Indicator for Patients with Gemcitabine-Treated Pancreatic Cancer. Co-author DOI 10.2147/cmar.s465098↗
  15. Construction of a novel model based on PVT1-MYC duet-related genes for predicting survival and characterization of the tumor microenvironment in pancreatic can… Co-author DOI 10.3389/fimmu.2024.1435593↗
  16. mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune mic… Co-author DOI 10.1016/j.canlet.2022.216020↗
  17. Epigenetic reprogramming-induced guanidinoacetic acid synthesis promotes pancreatic cancer metastasis and transcription-activating histone modifications. Co-author DOI 10.1186/s13046-023-02698-x↗
  18. Epidemiology of pancreatic cancer: New version, new vision. Co-author DOI 10.21147/j.issn.1000-9604.2023.05.03↗
  19. HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway. Co-author DOI 10.1002/mc.23420↗
  20. FGFR3 Nuclear Translocation Contributes to Proliferative Potential and Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002056↗
  21. Association between Temporal Glycemic Change and Risk of Pancreatic Cancer in Men: A Prospective Cohort Study. Co-author DOI 10.3390/cancers14143403↗
  22. Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review. Last author DOI 10.1002/cac2.12204↗
  23. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13402-020-00569-7↗
  24. Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. Co-author DOI 10.1016/j.canlet.2021.06.027↗
  25. The promoting effects of hsa_circ_0050102 in pancreatic cancer and the molecular mechanism by targeting miR-1182/NPSR1. Co-author DOI 10.1093/carcin/bgaa130↗
  26. Expression and Prognostic Value of Small Mothers Against Decapentaplegic 7, Matrix Metalloproteinase 2, and Matrix Metalloproteinase 9 in Resectable Pancreatic… Co-author DOI 10.1097/mpa.0000000000001892↗
  27. Clinicopathological and prognostic significance of ubiquitin-specific peptidase 15 and its relationship with transforming growth factor-β receptors in patients… Co-author DOI 10.1111/jgh.15244↗
  28. Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models. Co-author DOI 10.1158/1078-0432.ccr-19-3975↗
  29. Construction of a prognostic model with histone modification-related genes and identification of potential drugs in pancreatic cancer. Co-author DOI 10.1186/s12935-021-01928-6↗
  30. Targeting hypoxic tumor microenvironment in pancreatic cancer. Co-author DOI 10.1186/s13045-020-01030-w↗
  31. High-resolution Hi-C maps highlight multiscale 3D epigenome reprogramming during pancreatic cancer metastasis. Co-author DOI 10.1186/s13045-021-01131-0↗
  32. Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine. Co-author DOI 10.1186/s13046-020-01787-5↗
  33. Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-021-02152-w↗
  34. Quantitative assessment of the diagnostic role of mucin family members in pancreatic cancer: a meta-analysis. First author DOI 10.21037/atm-20-5606↗
  35. Comprehensive Analysis of Autophagy-Associated lncRNAs Reveal Potential Prognostic Prediction in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.596573↗
  36. The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells. Co-author DOI 10.3390/cells10030497↗
  37. The enhancement of glycolysis regulates pancreatic cancer metastasis. Co-author DOI 10.1007/s00018-019-03278-z↗
  38. Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2020.05.003↗
  39. Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1016/j.canlet.2020.06.011↗
  40. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study. Co-author DOI 10.1016/j.ebiom.2020.102767↗
  41. Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation. Co-author DOI 10.1038/s41388-020-1260-1↗
  42. Arginine metabolism: a potential target in pancreatic cancer therapy. Last author DOI 10.1097/cm9.0000000000001216↗
  43. Matrix Metalloproteinase 11 as a Novel Tumor Promoter and Diagnostic and Prognostic Biomarker for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001583↗
  44. Mucins in pancreatic cancer: A well-established but promising family for diagnosis, prognosis and therapy. First author DOI 10.1111/jcmm.15684↗
  45. Up-regulation of CDHR5 expression promotes malignant phenotype of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/jcmm.15856↗
  46. OLR1 Promotes Pancreatic Cancer Metastasis via Increased c-Myc Expression and Transcription of HMGA2. Co-author DOI 10.1158/1541-7786.mcr-19-0718↗
  47. Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory. Co-author DOI 10.1186/s12935-020-1147-9↗
  48. Metabolism of pancreatic cancer: paving the way to better anticancer strategies. Co-author DOI 10.1186/s12943-020-01169-7↗
  49. High Expression of MUC15 Is Correlated with Poor Prognosis of Pancreatic Cancer and Promotes Migration, Invasion, and Chemo-Resistance In Vitro. Co-author DOI 10.12659/msm.926432↗
  50. Transducin-Like Enhancer of Split-1 Inhibits Malignant Behaviors in vitro and Predicts a Better Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2020.00576↗

Closest collaborators

The 25 strongest of 134 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yupei Zhao · 60 shared papers, 2012–2026 · strength 7.04
  2. Taiping Zhang · 59 shared papers, 2012–2025 · strength 5.52
  3. Gang Yang · 35 shared papers, 2017–2025 · strength 4.04
  4. Li Zhou · 32 shared papers, 2012–2022 · strength 2.29
  5. Yu-Pei Zhao · 31 shared papers, 2011–2025 · strength 2.20
  6. Bo Ren · 12 shared papers, 2020–2025 · strength 2.04
  7. Fangyu Zhao · 17 shared papers, 2018–2024 · strength 1.88
  8. Yueze Liu · 14 shared papers, 2019–2026 · strength 1.86
  9. Zhe Cao · 19 shared papers, 2014–2024 · strength 1.81
  10. Jinshou Yang · 13 shared papers, 2019–2024 · strength 1.74
  11. Jie Ren · 8 shared papers, 2023–2025 · strength 1.65
  12. Zhiyong Liang · 18 shared papers, 2015–2022 · strength 1.63
  13. Mengyu Feng · 16 shared papers, 2017–2023 · strength 1.54
  14. Jiangdong Qiu · 13 shared papers, 2018–2025 · strength 1.53
  15. Wenhao Luo · 10 shared papers, 2019–2026 · strength 1.34
  16. Junchao Guo · 15 shared papers, 2014–2022 · strength 1.26
  17. Jiangdong Qiu · 9 shared papers, 2019–2024 · strength 1.25
  18. Guangyu Chen · 9 shared papers, 2020–2025 · strength 1.17
  19. Jianchun Xiao · 8 shared papers, 2019–2026 · strength 1.16
  20. Jun Lü · 10 shared papers, 2017–2022 · strength 1.11
  21. Menghua Dai · 6 shared papers, 2020–2021 · strength 0.83
  22. Yuan Fang · 4 shared papers, 2023–2024 · strength 0.81
  23. Xing Wang · 4 shared papers, 2023–2025 · strength 0.81
  24. Jinxin Tao · 5 shared papers, 2021–2025 · strength 0.79
  25. Ming Cui · 6 shared papers, 2016–2025 · strength 0.78

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.